Black Rock Inc. Anebulo Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,761 shares of ANEB stock, worth $5,491. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,761

Previous 4,049 7.11%

Holding current value

$5,491

Previous $11,000 9.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.9 - $3.12 $547 - $898	-288 Reduced 7.11%	3,761 $10,000
Q1 2024 May 10, 2024	SELL	$2.34 - $3.0 $224 - $288	-96 Reduced 2.32%	4,049 $11,000
Q4 2023 Feb 13, 2024	SELL	$1.71 - $3.17 $82 - $152	-48 Reduced 1.14%	4,145 $10,000
Q3 2023 Nov 13, 2023	SELL	$2.15 - $3.49 $6,579 - $10,679	-3,060 Reduced 42.19%	4,193 $12,000
Q2 2023 Aug 11, 2023	SELL	$2.06 - $2.98 $576 - $834	-280 Reduced 3.72%	7,253 $17,000
Q1 2023 May 12, 2023	BUY	$2.27 - $3.25 $544 - $780	240 Added 3.29%	7,533 $21,000
Q4 2022 Feb 13, 2023	BUY	$1.79 - $3.39 $286 - $542	160 Added 2.24%	7,293 $17,000
Q3 2022 Nov 14, 2022	SELL	$2.8 - $5.49 $560 - $1,098	-200 Reduced 2.73%	7,133 $20,000
Q2 2022 Aug 12, 2022	SELL	$2.7 - $7.15 $324 - $858	-120 Reduced 1.61%	7,333 $38,000
Q1 2022 May 12, 2022	SELL	$6.0 - $7.7 $2,160 - $2,772	-360 Reduced 4.61%	7,453 $53,000
Q4 2021 Feb 10, 2022	BUY	$5.84 - $7.3 $1,168 - $1,460	200 Added 2.63%	7,813 $49,000
Q3 2021 Nov 09, 2021	SELL	$6.55 - $7.77 $1,048 - $1,243	-160 Reduced 2.06%	7,613 $50,000
Q2 2021 Aug 11, 2021	BUY	$6.58 - $8.95 $51,146 - $69,568	7,773 New	7,773 $53,000

Others Institutions Holding ANEB

# of Institutions

Shares Held

7.34M

Call Options Held

Put Options Held

View Full List

About Anebulo Pharmaceuticals, Inc.

Ticker ANEB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,633,200
Market Cap $37.4M
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...

More about ANEB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account